JAK2 and ovarian cancer: In ovarian cancer, the demethylase ALKBH5, which mediates JAK2 m6A demethylation to activate the JAK2/STAT3 signaling pathway, enhances resistance to cisplatin treatment (Nie et al., 2021a).